• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Wandercraft wins FDA clearance for exoskeleton for people with spinal cord injuries

Wandercraft wins FDA clearance for exoskeleton for people with spinal cord injuries

February 13, 2024 By Sean Whooley

Wandercraft Atalante X exoskeleton
The Atalante X exoskeleton system. [Image from Wandercraft]
Wandercraft announced today that it received FDA clearance for its Atalante X exoskeleton for individuals with spinal cord injuries (SCIs).

The FDA granted clearance for people with SCIs at levels T5 to L5 to utilize the self-balancing robotic exoskeleton technology. The system enables those with limited mobility to stand up and walk again.

Wandercraft says safety and efficacy data from more than 500 patients supported the regulatory nod. Atalante X already picked up FDA clearance for cerebrovascular accident in December 2022.

Wandercraft’s Atalante X exoskeleton features a powered ankle mechanism. It can perform complex ankle movements that enable wearers to mimic a natural human gait. This helps therapists better assist patients in their rehabilitation, the company said.

Therapists can help users stand up and walk in the exoskeleton, including in their very first session. The wearer can take steps in different directions and practice standing up in an upright, weight-bearing position. Wandercraft said users can also more easily transfer in and out of the device.

The company unveiled its Personal Exoskeleton, a self-balancing system for personal everyday use, in December 2023. Both Atalante X and the Personal Exoskeleton represent the company’s goal to help patients with limited mobility through their rehab journey.

“Today’s FDA clearance for individuals with spinal cord injuries speaks volumes about the amazing possibilities for Atalante X, as we seek to help as many patients as possible to stand and walk again,” Wandercraft CEO Matthieu Masselin said. “Wandercraft has achieved several key milestones over the last year including two FDA clearances, on top of the successful unveiling of our personal exoskeleton. I am proud of the hard work of the entire Wandercraft team, as we push forward with the ultimate vision of Atalante X- to support people with limited mobility through every step of their journey.”

Wearable robotics and exoskeletons are currently having their moment in the sun, it seems. Companies like Myomo and Lifeward (formerly ReWalk Robotics) are set to benefit from major Medicare changes around these devices. Lifeward CEO Larry Jasinski recently spoke to MassDevice about the future for the technology.

Filed Under: 510(k), Food & Drug Administration (FDA), Neurological, Prosthetics, Regulatory/Compliance, Spine, Surgical Robotics Tagged With: FDA, wandercraft

More recent news

  • Massachusetts Life Sciences Center offers grants to lower medtech commercial risk
  • The 10 largest medical device companies
  • CSL to drop Terumo for Haemonetics in US plasma collection supply deal
  • How 5 medtech CEOs design for access
  • Butterfly Network to chase ultrasound brain-computer interfaces with newcomer Bridge Neurotech

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy